Indication: Hematological Malignancies
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
Sub-indication: Hematological Malignancies
Drug Study
Principal Investigator: Don Stevens, M.D.Norton Cancer Institute
Sponsor: Pharmacyclics, LLC
Learn more at ClinicalTrials.gov
Email for more information: Heme-NCIResearch@nortonhealthcare.org